Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: A putative mechanism

Xin Zheng, Fei Chu, Pauline M. Chou, Christine Gallati, Usawadee Dier, Bernard L. Mirkin, Shaker A. Mousa, Abdelhadi Rebbaa

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Cathepsin L is a lysosomal enzyme thought to play a key role in malignant transformation. Recent work from our laboratory has demonstrated that this enzyme may also regulate cancer cell resistance to chemotherapy. The present study was undertaken to define the relevance of targeting cathepsin L in the suppression of drug resistance in vitro and in vivo and also to understand the mechanism(s) of its action. In vitro experiments indicated that cancer cell adaptation to increased amounts of doxorubicin over time was prevented in the presence of a cathepsin L inhibitor, suggesting that inhibition of this enzyme not only reverses but also prevents the development of drug resistance. The combination of the cathepsin L inhibitor with doxorubicin also strongly suppressed the proliferation of drug-resistant tumors in nude mice. An investigation of the underlying mechanism(s) led to the finding that the active form of this enzyme shuttles between the cytoplasm and nucleus. As a result, its inhibition stabilizes and enhances the availability of cytoplasmic and nuclear protein drug targets including estrogen receptor-α, Bcr-Abl, topoisomerase-IIα, histone deacetylase 1, and the androgen receptor. In support of this, the cellular response to doxorubicin, tamoxifen, imatinib, trichostatin A, and flutamide increased in the presence of the cathepsin L inhibitor. Together, these findings provided evidence for the potential role of cathepsin L as a target to suppress cancer resistance to chemotherapy and uncovered a novel mechanism by which protease inhibition-mediated drug target stabilization may enhance cellular visibility and, thus, susceptibility to anticancer agents.

Original languageEnglish (US)
Pages (from-to)C65-C74
JournalAmerican Journal of Physiology - Cell Physiology
Volume296
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Cathepsin L
Drug Resistance
Doxorubicin
Enzymes
Neoplasms
trichostatin A
Histone Deacetylase 1
Pharmaceutical Preparations
Flutamide
Drug Therapy
Type II DNA Topoisomerase
Androgen Receptors
Tamoxifen
Nuclear Proteins
Nude Mice
Estrogen Receptors
Antineoplastic Agents
In Vitro Techniques
Cytoplasm
Peptide Hydrolases

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cell Biology

Cite this

Zheng, Xin ; Chu, Fei ; Chou, Pauline M. ; Gallati, Christine ; Dier, Usawadee ; Mirkin, Bernard L. ; Mousa, Shaker A. ; Rebbaa, Abdelhadi. / Cathepsin L inhibition suppresses drug resistance in vitro and in vivo : A putative mechanism. In: American Journal of Physiology - Cell Physiology. 2009 ; Vol. 296, No. 1. pp. C65-C74.
@article{0d685b1a60234e679785120d4ff6e3d1,
title = "Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: A putative mechanism",
abstract = "Cathepsin L is a lysosomal enzyme thought to play a key role in malignant transformation. Recent work from our laboratory has demonstrated that this enzyme may also regulate cancer cell resistance to chemotherapy. The present study was undertaken to define the relevance of targeting cathepsin L in the suppression of drug resistance in vitro and in vivo and also to understand the mechanism(s) of its action. In vitro experiments indicated that cancer cell adaptation to increased amounts of doxorubicin over time was prevented in the presence of a cathepsin L inhibitor, suggesting that inhibition of this enzyme not only reverses but also prevents the development of drug resistance. The combination of the cathepsin L inhibitor with doxorubicin also strongly suppressed the proliferation of drug-resistant tumors in nude mice. An investigation of the underlying mechanism(s) led to the finding that the active form of this enzyme shuttles between the cytoplasm and nucleus. As a result, its inhibition stabilizes and enhances the availability of cytoplasmic and nuclear protein drug targets including estrogen receptor-α, Bcr-Abl, topoisomerase-IIα, histone deacetylase 1, and the androgen receptor. In support of this, the cellular response to doxorubicin, tamoxifen, imatinib, trichostatin A, and flutamide increased in the presence of the cathepsin L inhibitor. Together, these findings provided evidence for the potential role of cathepsin L as a target to suppress cancer resistance to chemotherapy and uncovered a novel mechanism by which protease inhibition-mediated drug target stabilization may enhance cellular visibility and, thus, susceptibility to anticancer agents.",
author = "Xin Zheng and Fei Chu and Chou, {Pauline M.} and Christine Gallati and Usawadee Dier and Mirkin, {Bernard L.} and Mousa, {Shaker A.} and Abdelhadi Rebbaa",
year = "2009",
month = "1",
day = "1",
doi = "10.1152/ajpcell.00082.2008",
language = "English (US)",
volume = "296",
pages = "C65--C74",
journal = "American Journal of Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "1",

}

Zheng, X, Chu, F, Chou, PM, Gallati, C, Dier, U, Mirkin, BL, Mousa, SA & Rebbaa, A 2009, 'Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: A putative mechanism', American Journal of Physiology - Cell Physiology, vol. 296, no. 1, pp. C65-C74. https://doi.org/10.1152/ajpcell.00082.2008

Cathepsin L inhibition suppresses drug resistance in vitro and in vivo : A putative mechanism. / Zheng, Xin; Chu, Fei; Chou, Pauline M.; Gallati, Christine; Dier, Usawadee; Mirkin, Bernard L.; Mousa, Shaker A.; Rebbaa, Abdelhadi.

In: American Journal of Physiology - Cell Physiology, Vol. 296, No. 1, 01.01.2009, p. C65-C74.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cathepsin L inhibition suppresses drug resistance in vitro and in vivo

T2 - A putative mechanism

AU - Zheng, Xin

AU - Chu, Fei

AU - Chou, Pauline M.

AU - Gallati, Christine

AU - Dier, Usawadee

AU - Mirkin, Bernard L.

AU - Mousa, Shaker A.

AU - Rebbaa, Abdelhadi

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Cathepsin L is a lysosomal enzyme thought to play a key role in malignant transformation. Recent work from our laboratory has demonstrated that this enzyme may also regulate cancer cell resistance to chemotherapy. The present study was undertaken to define the relevance of targeting cathepsin L in the suppression of drug resistance in vitro and in vivo and also to understand the mechanism(s) of its action. In vitro experiments indicated that cancer cell adaptation to increased amounts of doxorubicin over time was prevented in the presence of a cathepsin L inhibitor, suggesting that inhibition of this enzyme not only reverses but also prevents the development of drug resistance. The combination of the cathepsin L inhibitor with doxorubicin also strongly suppressed the proliferation of drug-resistant tumors in nude mice. An investigation of the underlying mechanism(s) led to the finding that the active form of this enzyme shuttles between the cytoplasm and nucleus. As a result, its inhibition stabilizes and enhances the availability of cytoplasmic and nuclear protein drug targets including estrogen receptor-α, Bcr-Abl, topoisomerase-IIα, histone deacetylase 1, and the androgen receptor. In support of this, the cellular response to doxorubicin, tamoxifen, imatinib, trichostatin A, and flutamide increased in the presence of the cathepsin L inhibitor. Together, these findings provided evidence for the potential role of cathepsin L as a target to suppress cancer resistance to chemotherapy and uncovered a novel mechanism by which protease inhibition-mediated drug target stabilization may enhance cellular visibility and, thus, susceptibility to anticancer agents.

AB - Cathepsin L is a lysosomal enzyme thought to play a key role in malignant transformation. Recent work from our laboratory has demonstrated that this enzyme may also regulate cancer cell resistance to chemotherapy. The present study was undertaken to define the relevance of targeting cathepsin L in the suppression of drug resistance in vitro and in vivo and also to understand the mechanism(s) of its action. In vitro experiments indicated that cancer cell adaptation to increased amounts of doxorubicin over time was prevented in the presence of a cathepsin L inhibitor, suggesting that inhibition of this enzyme not only reverses but also prevents the development of drug resistance. The combination of the cathepsin L inhibitor with doxorubicin also strongly suppressed the proliferation of drug-resistant tumors in nude mice. An investigation of the underlying mechanism(s) led to the finding that the active form of this enzyme shuttles between the cytoplasm and nucleus. As a result, its inhibition stabilizes and enhances the availability of cytoplasmic and nuclear protein drug targets including estrogen receptor-α, Bcr-Abl, topoisomerase-IIα, histone deacetylase 1, and the androgen receptor. In support of this, the cellular response to doxorubicin, tamoxifen, imatinib, trichostatin A, and flutamide increased in the presence of the cathepsin L inhibitor. Together, these findings provided evidence for the potential role of cathepsin L as a target to suppress cancer resistance to chemotherapy and uncovered a novel mechanism by which protease inhibition-mediated drug target stabilization may enhance cellular visibility and, thus, susceptibility to anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=58349113405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58349113405&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00082.2008

DO - 10.1152/ajpcell.00082.2008

M3 - Article

C2 - 18971393

AN - SCOPUS:58349113405

VL - 296

SP - C65-C74

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6143

IS - 1

ER -